The relationship between triglyceride/high-density lipoprotein cholesterol ratio and coronary slow-flow phenomenon.
Coronary slow-flow phenomenon
Thrombolysis in Myocardial Infarction frame count
Triglyceride/high-density lipoprotein cholesterol ratio
Journal
The international journal of cardiovascular imaging
ISSN: 1875-8312
Titre abrégé: Int J Cardiovasc Imaging
Pays: United States
ID NLM: 100969716
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
07
04
2021
accepted:
19
08
2021
pubmed:
29
8
2021
medline:
9
2
2022
entrez:
28
8
2021
Statut:
ppublish
Résumé
In this study, we aimed to investigate the relationship between high triglyceride (TG)/high-density lipoprotein cholesterol (HDL-C) ratio and coronary slow flow phenomenon (CSFP) in patients undergoing elective coronary angiography for suspected coronary artery disease. This prospective study included a total of 84 CSFP patients and 83 controls with normal coronary flow, as evidenced by coronary angiography. The Thrombolysis in Myocardial Infarction (TIMI) frame count (TFC) was used to measure the coronary blood flow velocity. The lipid profiles were analyzed and TG/HDL-C ratio were calculated dividing absolute TG levels by absolute HDL-C levels in peripheral blood. The median TG/HDL-C ratio was higher in the CSFP group than the control group (3.4 [2.6 to 4.9] vs. 2.3 [1.8 to 3], respectively; p < 0.001). The multivariate logistic regression analysis revealed that TG/HDL-C ratio was an independent predictor of CSFP (odds ratio [OR] 1.78, 95% confidence interval [CI] 1.59-2.32; p = 0.001) and TG/HDL-C ratio was positively correlated with the TFC in the CSFP group (r = 0.311, p < 0.001). The area under the receiver operating characteristic curve of TG/HDL-C for the diagnosis of CSFP was 0.73 (95% CI 0.65-0.81; p < 0.001). If a cut-off value of 2.75 was used, higher levels of TG/HDL-C ratio could predict the presence of CSFP with 72% sensitivity and 71% specificity. Our study results suggest that TG/HDL-C ratio is associated with CSFP and may be a useful biomarker for predicting CSFP and its severity.
Identifiants
pubmed: 34453654
doi: 10.1007/s10554-021-02387-w
pii: 10.1007/s10554-021-02387-w
doi:
Substances chimiques
Cholesterol, HDL
0
Triglycerides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5-13Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Tambe AA, Demany MA, Zimmerman HA, Mascarenhas E (1972) Angina pectoris and slow flow velocity of dye in coronary arteries—a new angiographic finding. Am Heart J 84:66–71
doi: 10.1016/0002-8703(72)90307-9
Saadat M, Masoudkabir F, Afarideh M, Ghodsi S, Vasheghani-Farahani A (2019) Discrimination between obstructive coronary artery disease and cardiac syndrome X in women with typical angina and positive exercise test; utility of cardiovascular risk calculators. Medicina (Kaunas) 55(1):12
doi: 10.3390/medicina55010012
Cin VG, Pekdemir H, Camsar A, Cicek D, Akkus MN, Parmaksyz T et al (2003) Diffuse intimal thickening of coronary arteries in slow coronary flow. Jpn Heart J 44:907–919
doi: 10.1536/jhj.44.907
Nan Li, Liuyang T, Jiefeng R et al (2019) Evaluation of homocysteine in the diagnosis and prognosis of coronary slow flow syndrome. Biomark Med 13(17):1439–1446
doi: 10.2217/bmm-2018-0446
Sezgin AT, Sigirci A, Barutcu I, Topal E, Sezgin N, Ozdemir R et al (2003) Vascular endothelial function in patients with slow coronary flow. Coron Artery Dis 14:155–161
doi: 10.1097/00019501-200304000-00008
Demir B, Caglar IM, Tureli HO, Pirhan O, Aciksari G et al (2014) Coronary slow flow phenomenon associated with high serum levels of soluble CD40 ligand and urotensin II: a multi-marker approach. Clin Lab 60:1909–1920
doi: 10.7754/Clin.Lab.2014.140316
Fragasso G, Chierchia SL, Arioli F et al (2009) Coronary slow-flow causing transient myocardial hypoperfusion in patients with cardiac syndrome X: long-term clinical and functional prognosis. Int J Cardiol 137:137–144
doi: 10.1016/j.ijcard.2008.06.070
Zhu X, Shen H, Gao F et al (2019) Clinical profile and outcome in patients with coronary slow flow phenomenon. Cardiol Res Pract 2019:9168153
doi: 10.1155/2019/9168153
Caliskan M, Erdogan D, Gullu H et al (2007) Effects of atorvastatin on coronary flow reserve in patients with slow coronary flow. Clin Cardiol 30(9):475–479
doi: 10.1002/clc.20140
Pekdemir H, Polat G, Cin VG, Çamsari A, Cicek D, Akkus MN, Doven O, Katircibası MT, Muslu N (2004) Elevated plasma endothelin-1 levels in coronary sinus during rapid rate atrial pacing in patients with coronary slow flow. Int J Cardiol 97(1):35–41
doi: 10.1016/j.ijcard.2003.06.025
Pekdemir H, Çamsarı A, Parmaksız T, Çiçek D, Katırcıbaşı MT, Akkuş N et al (2004) Slow coronary flow may be a sign of diffuse atherosclerosis. Contribution of FFR and IVUS. Acta Cardiol 59(2):127–133
doi: 10.2143/AC.59.2.2005166
Sanati H, Kiani R, Shakerian F, Firouzi A, Zahedmehr A, Peighambari M et al (2016) Coronary slow flow phenomenon clinical findings and predictors. Res Cardiovasc Med 5(1):e30296
doi: 10.5812/cardiovascmed.30296
Pearson TA (2017) Understanding the impact of hyperlipidemia treatment on medical expenditures for cardiovascular disease. Med Care 55(1):1–3
doi: 10.1097/MLR.0000000000000682
Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ et al (2017) American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease—executive Summary Complete Appendix to Guidelines. Endocr Pract 23(4):479–497
doi: 10.4158/EP171764.GL
Carmena R, Duriez P, Fruchart JC (2004) Atherogenic lipoprotein particles in atherosclerosis. Circulation 109:2–7
doi: 10.1161/01.CIR.0000131511.50734.44
Zhu L, Lu Z, Zhu L et al (2015) Lipoprotein ratios are better than conventional lipid parameters in predicting coronary heart disease in Chinese Han people. Kardiol Pol 73:931–938
doi: 10.5603/KP.a2015.0086
Millan J, Pinto X, Munoz A, Zuniga M, Rubies-Prat J, Pallardo LF et al (2009) Lipoprotein ratios: physiological significance and clinical usefulness in cardiovascular prevention. Vasc Health Risk Manage 5:757–765
Gaziano JM, Hennekens CH, O’Donnell CJ, Breslow JL, Buring JE (1997) Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation 96(8):2520–2525
doi: 10.1161/01.CIR.96.8.2520
Wan K, Zhao J, Huang H et al (2015) The association between triglyceride/high-density lipoprotein cholesterol ratio and all-cause mortality in acute coronary syndrome after coronary revascularization. PLoS ONE 10:e0123521
doi: 10.1371/journal.pone.0123521
Quispe R, Manalac RJ, Faridi KF et al (2015) Relationship of the triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio to the remainder of the lipid profile: the very large database of lipids-4 (VLDL-4) study. Atherosclerosis 242:243–250
doi: 10.1016/j.atherosclerosis.2015.06.057
Sultani R, Tong DC, Peverelle M et al (2020) Elevated triglycerides to high-density lipoprotein cholesterol (TG/HDL-C) ratio predicts long-term mortality in high-risk patients. Heart Lung Circ 29:414–421
doi: 10.1016/j.hlc.2019.03.019
Gibson CM, Cannon CP, Daley WL, Dodge JT Jr, Alexander B Jr, Marble SJ, McCabe CH, Raymond L, Fortin T, Poole WK, Braunwald E (1996) TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation 93:879–888
doi: 10.1161/01.CIR.93.5.879
Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18(6):499–502
doi: 10.1093/clinchem/18.6.499
Youden WJ (1950) Index for rating diagnostic tests. Cancer 3(1):32–35
doi: 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3
Avşar O, Demir I, Ekiz O et al (2007) Relationship between the slow coronary flow and carotid artery intima-media thickness. Anadolu Kardiyol Derg 7(1):19–23
pubmed: 17347070
Camsari A, Ozcan T, Ozer C et al (2008) Carotid artery intima-media thickness correlates with intravascular ultrasound parameters in patients with slow coronary flow. Atherosclerosis 200:310–314
doi: 10.1016/j.atherosclerosis.2007.12.028
Davignon J, Ganz P (2004) Role of endothelial dysfunction in atherosclerosis. Circulation 109:27–32
Vakkilainen J, Steiner G, Ansquer JC et al (2003) Relationships between low-density lipoproteinparticle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Athero-sclerosis Intervention Study (DAIS). Circulation 107:1733–1737
doi: 10.1161/01.CIR.0000057982.50167.6E
Jørgensen AB, Frikke-Schmidt R, West AS, Grande P, Nordestgaard BG, Tybjærg-Hansen A (2013) Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur Heart J 34(24):1826–1833
doi: 10.1093/eurheartj/ehs431
Vinodhini WM, Keerthi K, Kumar JS, Subramaniyam G (2019) Assessment of remnant lipoprotein cholesterol (RLP-C) levels and its correlation with carotid intima media thickness in insulin resistant type 2 diabetes mellitus patients. J Clin Diagn Res 13:BC29–BC31
Sezgin AT, Barutcu I, Sezgin N, Gullu H, Esen AM, Acikgoz N et al (2006) Contribution of plasma lipid disturbances to vascular endothelial function in patients with slow coronary flow. Angiology 57(6):694–701
doi: 10.1177/0003319706295472
Kalaycı B, Kalaycı S, Kokturk F (2019) Proportional serum lipid parameters in coronary slow flow phenomenon Turkiye Klinikleri. J Cardiovasc Sci 31(1):21–28
Yilmaz H, Demir I, Uyar Z (2008) Clinical and coronary angiographic characteristics of patients with coronary slow flow. Acta Cardiol 63(5):579–584
doi: 10.2143/AC.63.5.2033224
Ding YD, Pei YQ, Wang R, Yang JX, Zhao YX, Liu XL, Shen H, Ma Q, Zhang S (2020) Ge HL Increased plasma lipoprotein-associated phospholipase A2 levels are associated with coronary slow flow. BMC Cardiovasc Disord 20(1):248
doi: 10.1186/s12872-020-01463-8
Yazici M, Demircan S, Aksakal E, Sahin M, Meriç M, Dursun I et al (2003) Plasma insulin, glucose and lipid levels, and their relations with corrected TIMI frame count in patients with slow coronary flow. Anadolu Kardiyol Derg 3(3):222–226
pubmed: 12967888
Alvarez C, Siu H (2018) Coronary slow-flow phenomenon as an underrecognized and treatable source of chest pain: case series and literature review. J Investig Med High Impact Case Rep 6:2324709618789194
pubmed: 30038914
pmcid: 6050810
Marinescu MA, Löffler AI, Ouellette M, Smith L, Kramer CM, Bourque JM (2015) Coronary microvascular dysfunction, microvascular angina, and treatment strategies. JACC Cardiovasc Imaging 8:210–220
doi: 10.1016/j.jcmg.2014.12.008